Associations of static anatomical geometry with planned dosimetric endpoints in prostate radiotherapy: a multicenter study - Report - MDSpire

Associations of static anatomical geometry with planned dosimetric endpoints in prostate radiotherapy: a multicenter study

  • By

  • Weixiang Lin

  • Yongwen Fang

  • Ying Chen

  • Chongmin Liang

  • Zhanwei Li

  • Xiaosheng Lin

  • Jianlan Fang

  • Junwei Chen

  • Liangjie Xiao

  • July 6, 2026

  • 0 min

Share

Clinical Report: Relationships Between Static Anatomical Structures and Planned Dosimetric Outcomes in Prostate Radiotherapy

Overview

This multicenter analysis investigates the associations between static anatomical geometry and planned dosimetric endpoints in prostate radiotherapy, focusing on organ at risk (OAR) dose metrics.

Background

External beam radiotherapy (EBRT) is a primary treatment for localized prostate cancer, with advancements in techniques like IMRT and IGRT enhancing dose conformality. However, anatomical variations can lead to significant dosimetric changes, affecting both target coverage and OAR exposure.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Bladder volume and longitudinal extent were associated with multiple bladder DVH endpoints.
  • Near-zero bladder D2cc values indicated geometric separation from the high-dose region.
  • The analysis utilized a unified multicenter workflow for data processing and quality control.
  • Target coverage metrics were analyzed as secondary exploratory endpoints.
  • The same processing workflow was applicable to an independent institutional DICOM cohort.

Clinical Implications

Clinicians should be aware of the potential impact of inter-patient anatomical variations on dosimetric outcomes.

Conclusion

This study highlights the association of anatomical geometry with planned dosimetric outcomes for prostate radiotherapy.

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: a dosimetric comparison
  2. The ASCO Post, 2013 -- Similar 15-year Functional Outcomes after Prostatectomy or Radiotherapy for Localized Prostate Cancer
  3. The ASCO Post, 2012 -- Prostate Cancer Studies Compare Outcomes, Toxicities, and Costs Related Articles
  4. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026) - PubMed
  5. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer | New England Journal of Medicine
  6. Can the Dose Constraints Be Trusted? Actual Dose Exposure of Bladder and Rectum During Prostate Cancer Radiotherapy - PubMed
  7. The ASCO Post — Prostate Cancer Studies Compare Outcomes, Toxicities, and Costs Related Articles
  8. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026) - PubMed
  9. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer | New England Journal of Medicine
  10. Can the Dose Constraints Be Trusted? Actual Dose Exposure of Bladder and Rectum During Prostate Cancer Radiotherapy - PubMed

Original Source(s)

Related Content